CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for HTG Molecular Diagnostics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

HTG Molecular Diagnostics Inc
3430 E Global Loop
TUCSON, AZ  85706-5009  United States Ticker: HTGMQHTGMQ
Filed for Bankruptcy on 6/5/2023
Case #23-10732, filed in the U.S. Bankruptcy Court for the District of Delaware
Business Summary
HTG Molecular Diagnostics, Inc. is a life science company. The Company is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The Company is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202312/31/2022YesYesYes--

Industries
SIC Code Description
3826 Laboratory analytical instruments
3845 Electromedical and electrotherapeutic apparatus
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chair of Board of Directors Ann F.Hanham 70 1/1/2021 8/25/2016
President, Chief Executive Officer, Director John L.Lubniewski 59 4/30/2019 4/1/2011
Senior Vice President, Chief Financial Officer, Treasurer, Secretary Shaun D.Mcmeans 61 5/23/2019 2/1/2012
5 additional Officers and Directors records available in full report.

Business Names
Business Name
HTG Molecular Diagnostics France SARL
HTG, Inc.
HTGM
HTGMQ

General Information
Number of Employees: 53 (As of 12/31/2022)
Outstanding Shares: 2,214,233 (As of 5/5/2023)
Shareholders: 57
Stock Exchange: OTC
Federal Tax Id: 860912294
Fax Number: (520) 547-2837
Email Address: info@htgenomics.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024